Lidman (300289.SZ) subsidiary's restructuring of Group B meningococcal vaccine clinical trial application approved.

Zhitong Finance APP News, Lideman (300289.SZ) announced that it recently received a report from its subsidiary Beijing Xiansheng Xiangrui Biological Products Co., Ltd. (referred to as "Xiansheng Xiangrui") stating that the recombinant group B meningococcal vaccine (Escherichia coli) developed by Xiansheng Xiangrui has obtained the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration. This drug will conduct clinical trials for the prevention of epidemic meningitis caused by group B Neisseria meningitidis.